BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL
BASEL, BS 4058
$161.25M
Total Contract Value
19 awards
First Award
Apr 28, 2022
Last Award
Sep 24, 2025
Business Size
small
CAGE Code
SSU10
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541714 | $92.50M | 5 |
| 541711 | $1.90M | 9 |
Contract Awards
6 awards found
HHSO100201600002C
Department of Health and Human Services
$-119,229.46
Sep 18, 2025
ADVANCED DEVELOPMENT OF CEFTOBIPROLE
NAICS: 541711 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGYFY2025
75A50124C00033
Department of Health and Human Services
$24.71M
Sep 15, 2025
THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA - EXECUTE CLIN 0003
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2025
75A50124C00033
Department of Health and Human Services
$39.11M
Jul 7, 2025
THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2025
HHSO100201600002C
Department of Health and Human Services
$-1,142,051.81
Sep 25, 2024
ADVANCED DEVELOPMENT OF CEFTOBIPROLE
NAICS: 541711 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGYFY2024
75A50124C00033
Department of Health and Human Services
$28.68M
Sep 18, 2024
THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2024
HHSO100201600002C
Department of Health and Human Services
$3.16M
Sep 28, 2022
ADVANCED DEVELOPMENT OF CEFTOBIPROLE
NAICS: 541711 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGYFY2022
Business Details
- UEI
- UA43HWRNXFS3
- CAGE Code
- SSU10
- Address
- GRENZACHERSTRASSE 487
BASEL, 4058
Parent Company
BASILEA PHARMACEUTICA INTERNATIONAL AG
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov